SCHEMBL525939

SCHEMBL525939

O=[N+]([O-])c1ccc(F)cc1CBr

nearest known ligand 0.58

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
TDP1 Q9NUW8 2/20 0.58
ATM Q13315 1/20 0.58
ALDH1A1 P00352 6/20 0.44
MAPT P10636 4/20 0.44
MAPK1 P28482 1/20 0.44
SNCA P37840 4/20 0.43
HSPB1 P04792 3/20 0.41
RIPK1 Q13546 1/20 0.40
HTT P42858 2/20 0.40
L3MBTL1 Q9Y468 2/20 0.40
SMN1; SMN2 Q16637 1/20 0.40
PDE7A Q13946 1/20 0.40
POLB P06746 1/20 0.39
TSHR P16473 2/20 0.39
HIF1A Q16665 1/20 0.39
GAA P10253 1/20 0.38
ALDH3A1 P30838 1/20 0.38
CYP3A4 P08684 1/20 0.37
VCAM1 P19320 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30800770 1.00 TDP1 (0.58) TDP1ATMALDH1A1MAPTMAPK1
SCHEMBL5194061 0.86 TDP1 (0.55) TDP1ATMALDH1A1MAPTMAPK1
SCHEMBL30074087 0.85 ATM (0.53) TDP1ATMALDH1A1MAPTMAPK1
SCHEMBL1972244 0.85 ATM (0.53) TDP1ATMALDH1A1MAPTMAPK1
SCHEMBL29362511 0.83 TDP1 (0.60) TDP1ATMALDH1A1MAPTMAPK1
SCHEMBL310839 0.83 TDP1 (0.60) TDP1ATMALDH1A1MAPTMAPK1
SCHEMBL2891144 0.81 TDP1 (0.58) TDP1ATMALDH1A1MAPTMAPK1
SCHEMBL10757303 0.81 ATM (0.58) TDP1ATMALDH1A1MAPTMAPK1
SCHEMBL1414035 0.81 ATM (0.58) TDP1ATMALDH1A1MAPTMAPK1
SCHEMBL28035706 0.80 TDP1 (0.56) TDP1ATMALDH1A1MAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250084055-A1 DIHYDROQUINOLINONES FOR MEDICAL TREATMENT C4 THERAPEUTICS, INC. (US) 2025-03-13 US disclosed
US-12091397-B2 Dihydroquinolinones for medical treatment C4 THERAPEUTICS, INC. 2024-09-17 US disclosed
CN-111278816-B Dihydro quinolinones C4医药公司 2024-03-15 CN disclosed
US-RE49698-E1 Substituted dihydroquinazolines AIC246 AG & CO. KG (DE) 2023-10-17 US disclosed
US-20230192643-A1 DIHYDROQUINOLINONES FOR MEDICAL TREATMENT C4 THERAPEUTICS, INC. (US) 2023-06-22 US disclosed
US-11401256-B2 Dihydroquinolinones for medical treatment C4 THERAPEUTICS, INC. (US) 2022-08-02 US disclosed
EP-3679028-A1 DIHYDROQUINOLINONES C4 Therapeutics, Inc. (US) 2020-07-15 EP disclosed
US-20200207733-A1 DIHYDROQUINOLINONES FOR MEDICAL TREATMENT C4 THERAPEUTICS, INC. (US) 2020-07-02 US disclosed
CN-111278816-A Dihydroquinolinones C4医药公司 2020-06-12 CN disclosed
WO-2019043208-A1 DIHYDROQUINOLINONES F. HOFFMANN-LA ROCHE AG (CH) 2019-03-07 WO disclosed
EP-0382687-A2 Benzofused-N-containing heterocycle derivatives BOEHRINGER INGELHEIM ITALIA S.p.A. (IT) 1990-08-16 EP disclosed
US-4783467-A Tetrahydroimidazoquinazolinone inotropic agents PFIZER INC. (US) 1988-11-08 US disclosed
EP-0232912-A1 Hydroxamic acids of 7-oxabicycloheptane substituted ethers E.R. Squibb & Sons, Inc. (US) 1987-08-19 EP disclosed
US-4654367-A ANTIALLERGY, ANTIINFLAMMATORY, ANTIPSORIATIC, PROSTAGLANDINS E. R. SQUIBB & SONS, INC. (US) 1987-03-31 US disclosed
US-4638012-A 7-oxabicycloheptane α-substituted ketone prostaglandin analogs useful in the treatment of thrombotic disease E. R. SQUIBB & SONS, INC. (US) 1987-01-20 US disclosed
EP-0205280-A2 Tetrahydroimidazoquinazolinone cardiac stimulants Pfizer Limited (GB) 1986-12-17 EP disclosed
US-4623650-A BACTERICIDES PFIZER INC. (US) 1986-11-18 US disclosed
EP-0184384-A1 Substituted dihydroquinolone carboxylic acids, anti-bacterial compositions containing them PFIZER INC. (US) 1986-06-11 EP disclosed
EP-0052912-B1 7-FLUORO-DIBENZO(B,F)THIEPIN DERIVATIVES, THEIR PREPARATION AND RESOLUTION, AND COMPOSITIONS CONTAINING THEM MERCK & CO. INC. (US) 1985-02-06 EP disclosed
EP-0052912-A1 7-Fluoro-dibenzo(b,f)thiepin derivatives, their preparation and resolution, and compositions containing them MERCK & CO. INC. (US) 1982-06-02 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12091397-B2 Dihydroquinolinones for medical treatment CRBN, RBX1, ADRM1 TDP1 2908/4885ATM 849/4885ALDH1A1 2816/4885
US-20230192643-A1 DIHYDROQUINOLINONES FOR MEDICAL TREATMENT CRBN, RBX1, ADRM1 TDP1 2908/4885ATM 849/4885ALDH1A1 2816/4885
US-20250084055-A1 DIHYDROQUINOLINONES FOR MEDICAL TREATMENT CRBN, RBX1, ADRM1 TDP1 2908/4885ATM 849/4885ALDH1A1 2816/4885
US-20200207733-A1 DIHYDROQUINOLINONES FOR MEDICAL TREATMENT CRBN, RBX1, ADRM1 TDP1 2908/4885ATM 849/4885ALDH1A1 2816/4885
US-11401256-B2 Dihydroquinolinones for medical treatment CRBN, RBX1, ADRM1 TDP1 2908/4885ATM 849/4885ALDH1A1 2816/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.